Lymphotoxin-.alpha./.beta. complexes and anti-lympotoxin-.beta. receptor antibodies as anti-tumor agents
US6312691A · kind A · utility
Inventors
Key dates
| Filing date | Jun 5, 1998 |
| Grant date | Nov 6, 2001 |
| Priority date | — |
| Expiry date | Jun 5, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compositions and methods useful for activating LT-.beta. receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-.alpha. and multiple subunits of lymphotoxin-.beta., which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-.beta. receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-.beta. receptor which act as lymphotoxin-.beta. receptor activating agents alone or in combination with other lymphotoxin-.beta. receptor activating agents either in the presence or absence of lymphotoxin-.alpha./.beta. complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-.beta. receptor antibodies either alone or in the presence of other lymphotoxin-.beta. receptor activating agents to potentiate tumor cell cytotoxicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.